225 related articles for article (PubMed ID: 26882365)
1. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
Mitchell P; Annemans L; Gallagher M; Hasan R; Thomas S; Gairy K; Knudsen M; Onwordi H
Br J Ophthalmol; 2012 May; 96(5):688-93. PubMed ID: 22399690
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Dewan V; Lambert D; Edler J; Kymes S; Apte RS
Ophthalmology; 2012 Aug; 119(8):1679-84. PubMed ID: 22503301
[TBL] [Abstract][Full Text] [Related]
4. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
Holekamp N; Duff SB; Rajput Y; Garmo V
J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
[No Abstract] [Full Text] [Related]
7. A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
Taylor M; Serbetci E; Ferreira A; Gairy K; Lewis L; Blouin J; Mitchell P
J Med Econ; 2014 Jun; 17(6):423-34. PubMed ID: 24673384
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
9. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
11. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
Kitano S; Sakamoto T; Goto R; Fukushima A; Vataire AL; Hikichi Y
J Med Econ; 2019 Mar; 22(3):254-265. PubMed ID: 30550375
[TBL] [Abstract][Full Text] [Related]
12. Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Smiddy WE
Ophthalmology; 2016 Sep; 123(9):1912-8. PubMed ID: 27425822
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of treatment of diabetic macular edema.
Pershing S; Enns EA; Matesic B; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Jan; 160(1):18-29. PubMed ID: 24573663
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
Adedokun L; Burke C
Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Hutton DW; Glassman AR; Liu D; Sun JK;
JAMA Ophthalmol; 2023 Mar; 141(3):268-274. PubMed ID: 36729431
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
McCarthy G; Fenu E; Bennett N; Almond C
Adv Ther; 2019 Mar; 36(3):632-644. PubMed ID: 30726549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]